Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced three upcoming presentations at the European Respiratory Society (ERS) International Congress 2023. The congress will take place in Milan, Italy from September 9, 2023 to September 13, 2023.
Oral and Poster Presentation
Title: Dual αVβ6/αVβ1 integrin inhibitor bexotegrast reduces fibrogenesis in pathological cell populations present in the fibrotic human lung
Date: Sunday, September 10, 2023
Session: From the transcriptome landscape to innovative preclinical models in lung diseases
Session Time: 11:40 am CEST
Oral and Late Breaking Poster Presentation
Title: Safety, tolerability and antifibrotic activity if bexotegrast: Phase 2a INTEGRIS-IPF Study (NCT04396756)
Date: Sunday, September 10, 2023
Session: Novel research impacting clinical practice in interstitial lung disease
Session Time: 2:15 to 3:30 pm CEST
Late Breaking Poster Presentation
Title: Circulating ITGB6 levels are elevated in patients with IPF and reduced following lung transplant
Date: Monday, September 11, 2023
Session: Towards the identification of new biomarkers in pulmonary diseases
Session Time: 12:30 to 2:00 pm CEST
The abstracts to the above presentations can be found by searching the ERS International Congress 2023 Congress Programme.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.